Schizophrenia
Conditions
Keywords
Schizophrenia, Cariprazine, VRAYLAR
Brief summary
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess how safe and effective cariprazine is in treating adult participants with schizophrenia in Japan and Taiwan. Adverse events and change in disease activity will be assessed. Cariprazine (VRAYLAR) is an approved drug for the treatment of schizophrenia in the United States. In the first 6-week period, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In the next 18-week period, participants will have the option to receive 1 of 3 doses of cariprazine. Approximately 250 adult participants, 18-65 years of age with schizophrenia will be enrolled in approximately 55 sites across Taiwan and Japan. Participants will receive oral capsules of Cariprazine or placebo for the 6-week Double-blind Period (DBP). Upon completion of 6-week DBP, participants will be eligible to receive oral capsules of Cariprazine for additional 18 weeks in the Blinded Extension Period (BEP), followed by an 8-week safety follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Detailed description
Per the final protocol amendment 3, the number of dosing arms in the 6-week DBP of the study changed from 3 to 2. Participants enrolled in the study through Protocol Amendment 2 and who were randomized to the arm that was eliminated, remained in that arm through DBP and their data are displayed by that arm for the DBP portion of the study in participant flow, baseline characteristics and safety sections. Data for all endpoints are presented as planned per final SAP.
Interventions
DRUGCariprazine
Oral Capsule
DRUGPlacebo
Oral Capsule
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with schizophrenia at least 1 year before informed consent. * Experienced a persistent psychotic episode within 2 months prior to informed consent requiring treatment modifications as judged by the investigator or sub-investigator.
Exclusion criteria
\- History of clinically significant medical conditions or any other reason that the investigator (or subinvestigator) determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose of study drug until 8 weeks following last dose of study drug (up to 32 weeks) | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug. |
| Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6. | Baseline (Wk 0) to Week 6 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6 | Baseline (Wk 0) to Week 6 | Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6 | Baseline (Wk 0) to Week 6 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6 | Baseline (Wk 0) to Week 6 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) and Week 6 to Week 24 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
| Change in CGI-S Score From Baseline (Wk 0) to Week 6 | Baseline (Wk 0) to Week 6 | Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) and Week 6 to Week 24 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
| Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) and Week 6 to Week 24 | Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) and Week 6 to Week 24 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) and Week 6 to Week 24 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
| Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) and Week 6 to Week 24 | Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement. |
| Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6 | Baseline (Wk 0) to Week 6 | Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement. |
Countries
Japan, Taiwan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| DBP Placebo Participants received Placebo oral capsule daily for the 6-week Double Blind Period (DBP). Upon completion of 6week DBP, participants had the option to receive Cariprazine 1.5 mg oral capsule daily for an 18-week Blinded Extension Period (BEP). | 16 |
| DBP Cariprazine 3 mg Participants received Cariprazine 3 mg oral capsule daily for the 6-week DBP. Upon completion of 6-week DBP, participants had the option to receive Cariprazine 3 mg oral capsule daily for the 18-week BEP. | 5 |
| DBP Cariprazine 6 mg Participants received Cariprazine 6 mg oral capsule daily for the 6-week DBP. Upon completion of 6-week DBP, participants had the option to receive Cariprazine 3 mg oral capsule daily for the 18-week BEP. | 13 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blinded Extension Period (BEP) | other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blinded Extension Period (BEP) | Study terminated by sponsor | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blinded Extension Period (BEP) | Withdrawal by Subject | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Double Blind Period (DBP) | Withdrawal by Subject | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Total | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|---|
| Age, Continuous | 42.5 years STANDARD_DEVIATION 11.4 | 42.2 years STANDARD_DEVIATION 11.76 | 40.4 years STANDARD_DEVIATION 13.7 | 43.7 years STANDARD_DEVIATION 10.88 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 34 Participants | 16 Participants | 5 Participants | 13 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 34 Participants | 16 Participants | 5 Participants | 13 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| SCI-PANSS Total Score at Baseline | 94.3 score on a scale STANDARD_DEVIATION 8.33 | 94.6 score on a scale STANDARD_DEVIATION 8.7 | 99.8 score on a scale STANDARD_DEVIATION 8.17 | 91.8 score on a scale STANDARD_DEVIATION 7.37 |
| Sex: Female, Male Female | 13 Participants | 6 Participants | 1 Participants | 6 Participants |
| Sex: Female, Male Male | 21 Participants | 10 Participants | 4 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 16 | 0 / 5 | 0 / 13 | 0 / 10 | 0 / 4 | 0 / 10 | 0 / 5 | 0 / 1 | 0 / 4 | 0 / 10 | 0 / 4 | 0 / 10 |
| other Total, other adverse events | 12 / 16 | 2 / 5 | 10 / 13 | 7 / 10 | 3 / 4 | 6 / 10 | 3 / 5 | 0 / 1 | 2 / 4 | 4 / 10 | 0 / 4 | 2 / 10 |
| serious Total, serious adverse events | 0 / 16 | 0 / 5 | 0 / 13 | 1 / 10 | 1 / 4 | 0 / 10 | 0 / 5 | 0 / 1 | 1 / 4 | 0 / 10 | 1 / 4 | 0 / 10 |
Outcome results
Primary
Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6.
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Population: mITT Population includes all randomized participants who receive at least 1 dose of study drug and have both baseline and at least 1 postbaseline value during the DBP.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6. | -15.2 score on a scale | Standard Deviation 12.21 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6. | -5.6 score on a scale | Standard Deviation 10.38 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6. | -30.2 score on a scale | Standard Deviation 17.47 |
95% CI: [-4, 23.1]
95% CI: [-28.7, -1.4]
Primary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 8 weeks following last dose of study drug (up to 32 weeks)
Population: Safety Population includes all randomized participants who receive at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| DBP Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 12 Participants |
| DBP Cariprazine 3 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 2 Participants |
| DBP Cariprazine 6 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 10 Participants |
Secondary
Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24
Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Population: BEP population consisted of all participants who complete the 6-week DBP and received at least 1 dose of study drug during the BEP regardless of which treatment group they were randomized to during the DBP.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DBP Placebo | Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -0.8 score on a scale | Standard Deviation 0.84 |
| DBP Placebo | Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -0.4 score on a scale | Standard Deviation 1.14 |
| DBP Cariprazine 3 mg | Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -1.3 score on a scale | Standard Deviation 2.31 |
| DBP Cariprazine 3 mg | Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 0.0 score on a scale | Standard Deviation 0 |
| DBP Cariprazine 6 mg | Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -1.0 score on a scale | Standard Deviation 0.82 |
| DBP Cariprazine 6 mg | Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 0.0 score on a scale | Standard Deviation 0.82 |
Secondary
Change in CGI-S Score From Baseline (Wk 0) to Week 6
Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Population: mITT Population includes all randomized participants who receive at least 1 dose of study drug and have both baseline and at least 1 postbaseline value during the DBP.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DBP Placebo | Change in CGI-S Score From Baseline (Wk 0) to Week 6 | -0.6 score on a scale | Standard Deviation 0.92 |
| DBP Cariprazine 3 mg | Change in CGI-S Score From Baseline (Wk 0) to Week 6 | -0.4 score on a scale | Standard Deviation 0.55 |
| DBP Cariprazine 6 mg | Change in CGI-S Score From Baseline (Wk 0) to Week 6 | -1.3 score on a scale | Standard Deviation 1.25 |
95% CI: [-0.7, 1.2]
95% CI: [-1.7, 0.3]
Secondary
Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24
Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Population: BEP population consisted of all participants who complete the 6-week DBP and received at least 1 dose of study drug during the BEP regardless of which treatment group they were randomized to during the DBP.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DBP Placebo | Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -11.6 score on a scale | Standard Deviation 13.52 |
| DBP Placebo | Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -7.6 score on a scale | Standard Deviation 18.28 |
| DBP Cariprazine 3 mg | Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -5.0 score on a scale | Standard Deviation 14 |
| DBP Cariprazine 3 mg | Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 2.7 score on a scale | Standard Deviation 5.51 |
| DBP Cariprazine 6 mg | Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -13.3 score on a scale | Standard Deviation 20.19 |
| DBP Cariprazine 6 mg | Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -1.8 score on a scale | Standard Deviation 11.18 |
Secondary
Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6
Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Population: mITT Population includes all randomized participants who receive at least 1 dose of study drug and have both baseline and at least 1 postbaseline value during the DBP.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DBP Placebo | Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6 | -3.2 score on a scale | Standard Deviation 7.49 |
| DBP Cariprazine 3 mg | Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6 | -2.8 score on a scale | Standard Deviation 9.2 |
| DBP Cariprazine 6 mg | Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6 | -14.5 score on a scale | Standard Deviation 8.28 |
95% CI: [-8.9, 9.7]
95% CI: [-18.5, -4.1]
Secondary
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Population: BEP population consisted of all participants who complete the 6-week DBP and received at least 1 dose of study drug during the BEP regardless of which treatment group they were randomized to during the DBP.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -5.2 score on a scale | Standard Deviation 4.09 |
| DBP Placebo | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -1.6 score on a scale | Standard Deviation 3.78 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -6.7 score on a scale | Standard Deviation 9.29 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -1.0 score on a scale | Standard Deviation 1 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -6.0 score on a scale | Standard Deviation 9.76 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 2.0 score on a scale | Standard Deviation 4.16 |
Secondary
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Population: mITT Population includes all randomized participants who receive at least 1 dose of study drug and have both baseline and at least 1 postbaseline value during the DBP.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6 | -3.8 score on a scale | Standard Deviation 3.71 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6 | -0.4 score on a scale | Standard Deviation 3.78 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6 | -9.1 score on a scale | Standard Deviation 6.82 |
95% CI: [-0.9, 7.7]
95% CI: [-10.2, -0.3]
Secondary
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Population: BEP population consisted of all participants who complete the 6-week DBP and received at least 1 dose of study drug during the BEP regardless of which treatment group they were randomized to during the DBP.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -6.4 score on a scale | Standard Deviation 3.85 |
| DBP Placebo | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -2.8 score on a scale | Standard Deviation 4.09 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -5.0 score on a scale | Standard Deviation 6.24 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -1.3 score on a scale | Standard Deviation 2.52 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -5.3 score on a scale | Standard Deviation 9.64 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 2.3 score on a scale | Standard Deviation 4.19 |
Secondary
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Population: mITT Population includes all randomized participants who receive at least 1 dose of study drug and have both baseline and at least 1 postbaseline value during the DBP.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6 | -3.5 score on a scale | Standard Deviation 3.86 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6 | -0.2 score on a scale | Standard Deviation 3.27 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6 | -8.1 score on a scale | Standard Deviation 5.3 |
95% CI: [-1, 7.5]
95% CI: [-8.9, -0.4]
Secondary
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Population: BEP population consisted of all participants who complete the 6-week DBP and received at least 1 dose of study drug during the BEP regardless of which treatment group they were randomized to during the DBP.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -5.2 score on a scale | Standard Deviation 5.36 |
| DBP Placebo | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -0.2 score on a scale | Standard Deviation 4.38 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -4.3 score on a scale | Standard Deviation 7.51 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 0.3 score on a scale | Standard Deviation 0.58 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -6.8 score on a scale | Standard Deviation 6.6 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 1.5 score on a scale | Standard Deviation 6.03 |
Secondary
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Population: mITT Population includes all randomized participants who receive at least 1 dose of study drug and have both baseline and at least 1 postbaseline value during the DBP.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6 | -4.7 score on a scale | Standard Deviation 4.67 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6 | -2.2 score on a scale | Standard Deviation 3.35 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6 | -8.7 score on a scale | Standard Deviation 4 |
95% CI: [-2.5, 7.5]
95% CI: [-8, 0]
Secondary
Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Population: BEP population consisted of all participants who complete the 6-week DBP and received at least 1 dose of study drug during the BEP regardless of which treatment group they were randomized to during the DBP.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DBP Placebo | Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -19.2 score on a scale | Standard Deviation 19.52 |
| DBP Placebo | Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | -4.0 score on a scale | Standard Deviation 16.05 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -19.3 score on a scale | Standard Deviation 30.09 |
| DBP Cariprazine 3 mg | Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 2.0 score on a scale | Standard Deviation 4.58 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Baseline (Wk 0) to Week 24 | -22.5 score on a scale | Standard Deviation 25.16 |
| DBP Cariprazine 6 mg | Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24 | Week 6 to Week 24 | 6.0 score on a scale | Standard Deviation 17.51 |